The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines.
Read Article
Editor's note: This article originally appeared August 24, 2020, and is being shared again as part of RheumNow's "Best of 2020".
Read Article
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read Article
The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.
Read Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...
Read Article
The CDC has addressed the effects and the issues of domestic and international travel on its website. Below is a sampling of key advice.
Read Article
Editor's note: This article originally appeared September 9, 2020, and is being shared again as part of RheumNow's "Best of 2020". We hope you enjoy reading it again.
Read Article
Editor's note: this article originally appeared in August and is being shared again as part of RheumNow's "Best of 2020".
Read Article
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to review on this week's podcast.
Read Article
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Read Article
A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.
Read Article
On January 22nd, the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis; voclosporin is a calcineurin-inhibitor immunosuppressant indicated for use in combination with a background immunosuppressive therapy.
Read Article
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Read Article
The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ?
Read Article
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
Read Article
Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
Read Article
Zoom has become the slam dunk answer to the pandemic. With zoom you can avoid congregations, but still attend and belong. Because of zoom you can sustain your business and continue medical care. With zoom, learning moved from the classroom to the dining room for all.
Read Article
Amazingly, we made it through 2020, a most forgettable year.
Life was great in the first 3 months of 2020, and then COVID hit the fan and a pandemic steamroller derailed life as we knew it.
Read Article
A press release from the Montreal Heart Institute has announced that the COLCORONA clinical trial has provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo.
Read Article
